Pour sa part, Lahcen Ahansal a affirme que l'objectif essentiel de l'Association
AMRAD pour le Developpement qu'il preside vise a [beaucoup moins que]donner aux enfants de ces regions reculees et defavorisees la chance de suivre une scolarite normale a l'instar des enfants du meme age dans les centres urbains[beaucoup plus grand que].
AMRAD will contribute its patent estate, intellectual property and know-how pertaining to the therapeutic target, pre-clinical and development capabilities to the collaboration, and CAT will contribute its proprietary human antibody
AMRAD has been granted patents to the GM-CSF receptor target in Europe, USA and Australia, and patents are pending in Canada and Japan.
David Chiswell, Chief Executive Officer of CAT, commented, "We are extremely pleased to be entering this relationship with AMRAD to develop novel strategies for treating inflammatory disease.
Sandra Webb, Managing Director and Chief Executive Officer of AMRAD, added, "The number of antibodies which have been identified and are presently in development using CAT technology provides AMRAD with great confidence that the collaboration we have initiated with CAT will deliver vitally important new medicines and great commercial results.
CAT's collaborators include: Abbott, AMRAD, Elan, Eli Lilly, Genetics Institute, Genzyme, Human Genome Sciences, Immunex, Incyte, Merck &Co.
